Navigation Links
EpiCept Reports Regulatory Progress on Ceplene(TM)
Date:9/17/2007

that the development of our other apoptosis product candidates will not be successful, the risk that our ASAP technology will not yield any successful product candidates, the risk that clinical trials for NP-1 will not be successful, that NP-1 will not receive regulatory approval or achieve significant commercial success, the risk that our other product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later stage clinical trials, the risk that EpiCept will not obtain approval to market any of its product candidates, the risks associated with reliance on additional outside financing to meet its capital requirements, the risks associated with dependence upon key personnel, the risks associated with reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization of our product candidates; the cost, delays and uncertainties associated with our scientific research, product development, clinical trials and regulatory approval process; our history of operating losses since our inception; competition; litigation; risks associated with prior material weaknesses in our internal controls; and risks associated with our ability to protect our intellectual property. These factors and other material risks are more fully discussed in EpiCept's periodic reports, including its reports on Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and Exchange Commission. You are urged to carefully review and consider the disclosures found in EpiCept's filings which are available at http://www.sec.gov or at http://www.epicept.com. You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be wrong due to inaccurate assumptions, unknown risks or uncertainties or other risk factors.

'/>"/>
SOURCE EpiCept Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
2. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014 The Pulmonary Fibrosis ... data from more than 1,100 patients and families suffering ... Drug Administration (FDA) for the Patient-Focused Drug Development Meeting ... a new FDA initiative to seek patient input in ... therapeutic treatments. "We applaud the FDA for ...
(Date:9/16/2014)... , Sept. 16, 2014 Astellas announced ... of Business Communications & Advocacy, Urology in the ... Communications & Advocacy Margaret Long. In this role, Noland ... urology to patient and advocacy organizations, as well ... key strategic initiatives. Noland,s appointment is the latest ...
(Date:9/16/2014)... 2014  Aratana Therapeutics, Inc. (NASDAQ: ... licensing, developing and commercializing innovative biopharmaceutical products for ... an underwritten registered public offering of shares of ... being offered by Aratana Therapeutics. ... book-running managers for the offering.  ...
Breaking Medicine Technology:PFF Submits Survey Data From More Than 1,100 Pulmonary Fibrosis Patients And Families To U.S. Food And Drug Administration For Upcoming Drug Development Meeting 2PFF Submits Survey Data From More Than 1,100 Pulmonary Fibrosis Patients And Families To U.S. Food And Drug Administration For Upcoming Drug Development Meeting 3PFF Submits Survey Data From More Than 1,100 Pulmonary Fibrosis Patients And Families To U.S. Food And Drug Administration For Upcoming Drug Development Meeting 4Christy Noland to Lead Urology Advocacy and Communications for Astellas 2Aratana Therapeutics, Inc. Announces Proposed Public Offering 2
... Oct. 11 Merial, the Animal Health division ... ), announced today that Merial Animal Health Co. (China) held ... located in the Nanchang Hi-tech Development Zone, China. Merial ... the Group,s first production facility in China has been in ...
... , EXTON, Pa., Oct. 9 Kensey Nash Corporation (Nasdaq: ... earnings results for its first quarter ended September 30, 2009 ... , Joe Kaufmann, President and CEO, will be ... 22, 2009 at 9:00 A.M. Eastern Time. , ...
Cached Medicine Technology:Merial invests US $70 million in Nanchang, China 2Merial invests US $70 million in Nanchang, China 3Kensey Nash Corporation Announces Its First Quarter Fiscal Year 2010 Earnings Release Date and Teleconference 2
(Date:9/16/2014)... Paradigm Physical Therapy is proud to announce ... for their patients. Dry needling is a procedure that ... musculoskeletal problems. , In this invasive procedure, a solid ... and muscle to create a trigger point. Using repeated ... to deactivate and release the trigger point within seconds. ...
(Date:9/16/2014)... Florida (PRWEB) September 16, 2014 These new ... last 3 years to receive up to $10,000 in a ... program, as well as other state and federal programs, are ... to be paid back until you sell or move out ... is a 0% interest loan. There are no monthly payments ...
(Date:9/16/2014)... magnesium sulfate is routinely given to pregnant women at ... won,t provide any long-term benefits for infants. ... pregnant women, researchers in Australia found it had no ... those children when they were assessed at between 6 ... negate the fact that the drug is helpful in ...
(Date:9/16/2014)... able to predict when and how much various treatments ... part to new findings that researchers at Fox Chase ... Oncology,s 56th Annual Meeting on Tuesday, September 16. , ... completed by men diagnosed with prostate cancer, Fox Chase ... following each type of treatment, and by how much. ...
(Date:9/16/2014)... September 16, 2014 This year’s theme ... and Sustainable company Glen Mills, Pennsylvania, September 15, 2014- ... one of the fastest growing companies in the country, ... flower, shrub, and tree health-care by naturally decreasing disease ... development. Today it announced that it will hold its ...
Breaking Medicine News(10 mins):Health News:Paradigm Physical Therapy Introduces Dry Needling 2Health News:New Updated 2014 First Time Home Buyer Programs Available to Florida Residents 2Health News:New Updated 2014 First Time Home Buyer Programs Available to Florida Residents 3Health News:Researchers Don't See Long-Term Benefits From Drug for Preemies 2Health News:Study identifies when and how much various prostate cancer treatments will impact urinary and sexual functioning 2Health News:Study identifies when and how much various prostate cancer treatments will impact urinary and sexual functioning 3Health News:Holganix Holds 3rd Annual Bionutritional Summit in Louisville, Kentucky 2
... Calif., May 27 The Ensign,Group, Inc. (Nasdaq: ... Ensign(TM) group of,skilled nursing, rehabilitative care services and ... in the FBR Capital,Markets 12th Annual Spring Investor ... in New York City. Christopher Christensen, CEO, together ...
... provide the infrastructure for MRF,s collaborative ... ... 27 Collaborative Drug,Discovery, Inc. (CDD) announced today that its ... new drug,candidates, has been selected by the Myelin Repair Foundation ...
... infection following operations for which a "prophylactic" antibiotic is ... than it was just a decade ago, according to ... report their findings in the June 15 issue of ... that have been associated with severe infections, such as ...
... dad is more involved in baby,care than ever before. Whether ... basics, or a new dad to whom the dear wife ... to pack in the "diaper,dude":, The Moms on Call ... pediatric nurse moms, is a guidebook for new dads that ...
... study says , , TUESDAY, May 27 (HealthDay News) -- A ... in nonsmokers, researchers report. , The findings -- that certain ... lung cancer, regardless of whether he or she ever smoked ... said study author Dr. Ping Yang, of the Mayo Clinic. ...
... 27 Somanetics Corporation,(Nasdaq: SMTS ) announced today ... and Drug Administration (FDA) to expand the labeling for ... 510(k) will serve to support our ongoing efforts,in the ... said,Bruce Barrett, Somanetics, president and CEO. "First, the 510(k) ...
Cached Medicine News:Health News:The Ensign Group to Present at the FBR Capital Markets 12th Annual Spring Investor Conference on May 29th 2Health News:The Ensign Group to Present at the FBR Capital Markets 12th Annual Spring Investor Conference on May 29th 3Health News:Collaborative Drug Discovery and Myelin Repair Foundation Announce Partnership 2Health News:Collaborative Drug Discovery and Myelin Repair Foundation Announce Partnership 3Health News:Collaborative Drug Discovery and Myelin Repair Foundation Announce Partnership 4Health News:The balance shifts 2Health News:Father's Day is Almost Here: Two Pediatric Nurses, Moms, Offer Practical Guidebook & DVD for New Dads 2Health News:Common Genetic Variant Tied to Lung Cancer Risk 2Health News:Common Genetic Variant Tied to Lung Cancer Risk 3Health News:Somanetics Receives 510(k) Clearance From the FDA to Expand INVOS System Labeling 2
Featuring a secure and tamper-evident adhesive closure, computer-generated Smart ScanBand can be simultaneously printed with bar code information and programmed with RFID information....
Safe. Reliable. Baby-friendly. ,The Hugs infant protection system helps to protect your infants and children from the threat of abduction....
VerdaSee Portal ID is a family of solutions that provide automated tracking and tracing of assets as they enter or leave designated areas within a healthcare facility....
... Agility is positioned to support ... to reduce medication and other ... workflow for pharmacy support staff ... blood products, lab specimens and ...
Medicine Products: